Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
Neurogene Inc. has an updated ownership report from Redmile-affiliated investors. Redmile Group, LLC and its principal, Jeremy C. Green, each report beneficial ownership of 1,572,202 shares of common stock, representing 9.9% of the outstanding class, all held through investment vehicles they manage.
Redmile Biopharma Investments I, L.P. reports beneficial ownership of 812,033 shares, or 5.1% of the common stock. These positions include 160,003 shares issuable upon exercise of pre-funded warrants. The percentages are calculated using 15,801,901 shares outstanding as of May 8, 2026, plus the warrant shares. Voting and dispositive power is shared among the Redmile entities, and both Redmile and Jeremy Green disclaim beneficial ownership beyond their pecuniary interests.
Neurogene Inc. received an updated ownership report from Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai. As of June 30, 2026, the filers may be deemed to beneficially own 714,885 shares of Neurogene common stock, all held directly by Trails Edge Biotechnology.
This position represents 4.5% of the outstanding shares, based on 15,801,901 shares reported outstanding as of May 8, 2026. Each filer reports sole voting and dispositive power over the 714,885 shares and indicates ownership of 5 percent or less of this class.
Balyasny Asset Management and affiliated entities report a significant ownership position in Neurogene Inc. They may be deemed to beneficially own 818,706 shares of Neurogene common stock, representing 5.18% of the class based on 15,801,901 shares outstanding as of May 8, 2026. The shares are held directly by Atlas Diversified Master Fund, Ltd., for which Balyasny Asset Management L.P. acts as investment manager. Through their control relationships, BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny may each be deemed to share this beneficial ownership, with sole voting and dispositive power over the 818,706 shares.
Neurogene Inc. is a clinical-stage biotech focused on gene therapies for severe neurological diseases, led by NGN‑401 for Rett syndrome. For the six months ended June 30, 2026, it reported a net loss of $65.4 million, widening from $44.7 million a year earlier, driven mainly by higher Rett clinical and manufacturing spend and increased stock‑based compensation.
Research and development expenses rose to $50.6 million, while general and administrative expenses increased to $19.4 million. Cash, cash equivalents and short‑term investments totaled $225.4 million at June 30, 2026, with net cash used in operating activities of $49.9 million.
Subsequent to quarter end, Neurogene completed a July 2026 underwritten offering of common stock and pre‑funded warrants, raising $143.8 million gross and $134.8 million net. Management states that, after this raise, existing cash and investments are expected to fund operations into the first quarter of 2029, supporting the ongoing registrational Embolden trial of NGN‑401 and manufacturing scale‑up activities.
Neurogene Inc. reported second quarter 2026 results and provided extensive updates on its NGN-401 gene therapy for Rett syndrome. Phase 1/2 data as of June 16, 2026 showed that 100% of 10 participants improved on the CGI-I scale and gained at least one developmental milestone, with a total of 47 milestones and an average of 4.7 per participant, and no plateau or loss of milestones through 30 months. NGN-401 at the 1E15 vg dose was generally well-tolerated across 35 treated participants as of August 10, 2026. Enrollment and dosing in the Embolden registrational trial (N=25) are complete, with topline data anticipated in the second half of 2027 and BLA-enabling PPQ runs expected to complete by year-end 2026.
Neurogene strengthened its balance sheet with an oversubscribed public follow-on offering generating approximately $144 million in gross proceeds and about $134.8 million in net proceeds, extending its cash runway into the first quarter of 2029. Cash, cash equivalents and short-term investments were $225.4 million as of June 30, 2026, or about $360.2 million on a pro forma basis including the offering. For the quarter, R&D expenses were $25.5 million versus $19.4 million a year earlier, G&A expenses were $11.2 million versus $6.7 million, and net loss was $34.5 million versus $22.0 million, reflecting higher development, stock-based compensation and pre-commercial spending.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on two days at weighted average prices around the mid-$36 range.
After these transactions, she reports ownership of 84,040 shares, which includes 10,635 restricted stock units scheduled to vest on March 13, 2027, 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028, and 22,000 restricted stock units vesting annually from February 20, 2027 through February 20, 2029. The filing notes that following completion of these sales she no longer holds any shares jointly with her spouse.
Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock. The sales occurred on July 1–2, 2026 in three tranches at weighted average prices around $34–$35 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and involved shares held jointly with her spouse. Following these sales, she continues to directly hold 88,840 shares, along with additional unvested restricted stock units scheduled to vest between 2027 and 2029.
Neurogene Inc. entered into an underwriting agreement to complete a public offering of its common stock and pre-funded warrants. The company is issuing 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 each. Underwriters exercised in full a 30‑day option to buy an additional 624,999 shares at the public offering price, less underwriting discounts and commissions. Net proceeds from the offering, including the exercised option, are expected to be approximately $134.8 million after fees and expenses. The company states that these proceeds, together with existing cash and cash equivalents, should fund operating and capital needs into the first quarter of 2029.
Neurogene Inc. is offering 3,500,000 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase 666,666 shares. The public offering price is $30.00 per share. Net proceeds are expected to be approximately $117.2 million (or $134.8 million if the underwriters’ option is exercised in full). Delivery is expected on or about July 2, 2026. The prospectus supplement states the company intends to use proceeds to fund clinical development and pre-commercial activities for NGN-401, for working capital and general corporate purposes. Total common shares outstanding immediately after the offering are projected to be 19,115,786 (or 19,740,785 if the option is exercised in full), based on March 31, 2026 outstanding figures.
Neurogene Inc. proposes an offering of shares of common stock and pre-funded warrants to purchase common stock, together with shares issuable upon exercise of those warrants, via a preliminary prospectus supplement dated (subject to completion). The offering will fund continued development and pre-commercial activities for NGN-401 and for working capital.
The prospectus discloses 15,615,786 shares outstanding as of March 31, 2026, historical net tangible book value of $237.8 million ($15.23 per share) and recent Nasdaq closing price of $32.28 on June 29, 2026. Key terms include tradable common stock and non-listed pre-funded warrants exercisable at $0.000001 per share with ownership limitations.